Literature DB >> 6360466

Clinical pharmacokinetics of metoclopramide.

D N Bateman.   

Abstract

Metoclopramide is rapidly and well absorbed from the gastrointestinal tract, and in man undergoes variable first-pass metabolism (oral bioavailability 32 to 100%). In man, N-4 sulphate conjugation is an important pathway of metabolism and after oral administration the ratio of free to conjugated metoclopramide in urine correlates with the plasma AUC. The elimination half-life of metoclopramide is dose-dependent after both intravenous and oral administration of single doses between 5 and 20mg. Metabolic profiles in animal species studied are very different from man. The clearance of metoclopramide is reduced in patients with renal failure to approximately 50% of normals and the terminal half-life is prolonged; this is despite the fact that renal clearance of free drug accounts for only 20% of the administered dose in normals. Preliminary studies after 'high dose' metoclopramide demonstrate accumulation to high plasma concentrations with linear kinetics, suggesting that current high dose regimens are unnecessarily cumbersome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6360466     DOI: 10.2165/00003088-198308060-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  31 in total

1.  Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.

Authors:  C Morran; D C Smith; D A Anderson; C S McArdle
Journal:  Br Med J       Date:  1979-05-19

2.  Transformation and excretion of drugs in biological systems. II. Transformation of metoclopramide in rabbits.

Authors:  T Arita; R Hori; K Ito; K Ichikawa; T Uesugi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1970-08       Impact factor: 1.645

3.  Modification of metoclopramide GLC assay: application to human biological specimens.

Authors:  Y K Tam; J E Axelson; R Ongley
Journal:  J Pharm Sci       Date:  1979-10       Impact factor: 3.534

4.  High dose metoclopramide-preliminary pharmacokinetic studies.

Authors:  W D Taylor; D N Bateman
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

5.  Metoclopramide and renal failure.

Authors:  A Caralps
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

6.  The pharmacokinetics of metoclopramide in man with observations in the dog.

Authors:  D N Bateman; C Kahn; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

7.  Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography.

Authors:  C Graffner; P O Lagerström; P Lundborg; O Rönn
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

8.  Metoclopramide metabolism and determination by high-pressure liquid chromatography.

Authors:  L Teng; R B Bruce; L K Dunning
Journal:  J Pharm Sci       Date:  1977-11       Impact factor: 3.534

9.  Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy.

Authors:  S B Strum; J E McDermed; R W Opfell; L P Riech
Journal:  JAMA       Date:  1982-05-21       Impact factor: 56.272

Review 10.  Metoclopramide: a review of its pharmacological properties and clinical use.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

View more
  24 in total

1.  Metoclopramide in the treatment of diabetic gastroparesis.

Authors:  Allen Lee; Braden Kuo
Journal:  Expert Rev Endocrinol Metab       Date:  2010

Review 2.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

3.  Pharmacokinetics of metoclopramide in patients with liver cirrhosis.

Authors:  E Magueur; H Hagege; P Attali; E Singlas; J P Etienne; A M Taburet
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

4.  Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis.

Authors:  F Albani; M R Tamè; R De Palma; M Bernardi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs.

Authors:  Chelsea M Hosey; Rosa Chan; Leslie Z Benet
Journal:  AAPS J       Date:  2015-11-20       Impact factor: 4.009

6.  Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.

Authors:  Sierra Vig; Laurel Seibert; Myke R Green
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-31       Impact factor: 4.553

Review 7.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

8.  Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions.

Authors:  Chelsea M Hosey; Leslie Z Benet
Journal:  Mol Pharm       Date:  2015-04-23       Impact factor: 4.939

9.  Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients treated with cisplatin-containing chemotherapy regimens.

Authors:  H Havsteen; H Nielsen; M Kjaer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Identification of metoclopramide metabolites in the urine of cattle by gas chromatography-mass spectrometry and high-performance liquid chromatography-photodiode array detection.

Authors:  R D Jones; C D Blanton; J M Bowen
Journal:  Vet Res Commun       Date:  1993       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.